Menthol for Dyspnea Relief in Health and COPD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKU Leuven
About this trial
Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and/or neural related mechanisms for this relief in symptoms remain unknown. The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.
Eligibility criteria
Qualifiers
Age: 18 years of age or older
Able to speak, read, and write Dutch or English
Normal pulmonary function: forced expiratory volume in 1 second (FEV1) to forced vital capacity ratio>0.70; FEV1≥80%predicted (WP1 and 2 only)
Non-smoker or former smokers (smoke-free ≥12 months prior to enrolment) (WP1 and 2 only)
Disqualifiers
Contraindication to exercise testing (e.g., significant cardiovascular, musculoskeletal, neurological disease; see Table 4 from ERS/ATS consensus statement)
Significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could influence dyspnea and/or impair exercise capacity (with the exception of COPD in WP3 and 4)
Body mass index <18.5 or >35 kg/m2
An ulcer or tumor in the esophagus, a nasal septum deviation, or recent nasopharyngeal surgery
Trial design
Treatments tested in this trial
- Menthol inhalation
- Strawberry scent
- Menthol inhalation and facial airflow
- Strawberry scent and airflow to leg
- Menthol inhalation and airflow to leg
- Strawberry inhalation and facial airflow
Treatment groups
120 Participants
are divided into 13 treatment groups13
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov